Antiarrhythmic effect of parenteral magnesium on ventricular tachycardia associated with long QT syndrome.
Magnesium deficiency has been linked with cardiac arrhythmias and sudden cardiac death. Antiarrhythmic effects of intravenous magnesium in the patients who are not hypomagnesaemic were mainly demonstrated in the patients with acquired long QT syndrome. Parenteral administration should be considered in this type of ventricular tachycardia, because its use is safe and straightforward.
Kurita
T
T
National Cardiovascular Centre, Osaka, Japan.
D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D006801:Humans; D007262:Infusions, Intravenous; D008133:Long QT Syndrome / Q000188:drug therapy* / Q000503:physiopathology*; D008274:Magnesium / Q000008:administration & dosage / Q000627:therapeutic use*; D008275:Magnesium Deficiency / Q000150:complications / Q000503:physiopathology*; D008278:Magnesium Sulfate / Q000008:administration & dosage / Q000627:therapeutic use; D017180:Tachycardia, Ventricular / Q000188:drug therapy / Q000503:physiopathology*
D000889:Anti-Arrhythmia Agents; D008278:Magnesium Sulfate; D008274:Magnesium